
Can hospital superbugs chew up stents and implants? Here's what a new study says
The finding means that bacteria, such as the one they studied, could degrade medical implants, lead to infections at the site of the implant and cause infections that are harder to treat.
What did the researchers find?
There are bacteria in the environment that have developed the capacity to break down different types of plastics. So researchers wanted to see whether bacteria that cause infections in humans could also lead to such degradation within the body.
For the study, scientists looked for different pathogens with genes that could potentially produce enzymes similar to the ones that environmental bacteria use to degrade plastics. While they found several hits, they selected a Pseudomonas aeruginosa sample that came from a patient's wound. They isolated an enzyme — which they named Pap1— that could digest a type of bio-degradable plastic frequently used in medical devices called polycaprolactone (PCL) plastic. The researchers found that the enzyme degraded 78 per cent of the plastic sample in just seven days.
Importantly, the researchers found that the bacteria were not only degrading the plastic, they were also using it as their carbon source — effectively eating it. 'This means we need to reconsider how pathogens exist in the hospital environment. Plastics, including plastic surfaces, could potentially be food for these bacteria. Pathogens with this ability could survive for longer in hospitals,' Dr Ronan McCarthy, author and professor of biomedical sciences at Brunel University, said in a release.
Why is this concerning?
This is concerning for several reasons: One, bacteria could live on in hospitals or within a patient even when there aren't any other nutrients present. Two, they could degrade medical devices that use plastics, leading to their failure. This could lead to a rethink of materials that should be used for medical devices. Three, researchers found that the plastic-digesting bacteria could cause more severe infections. The researchers further found that the bacteria were using the broken down plastic molecules to create biofilms (a matrix made of sugars, proteins, fats and DNA) that make pathogens more resistant and difficult to treat. Four, degrading medical devices would also mean that the pathogens would be able to create pits and niches within the human body, where it could be shielded from the immune system and antibiotics, again causing difficult-to-treat infections.
Are there other pathogens that could have this ability?
Researchers found that other pathogens like Streptococcus pneumoniae, Klebsiella pneumoniae and Acinetobacter baumannii, too, carried genes that could potentially create plastic-digesting enzymes. More studies are needed. Importantly, the researchers found that Pap1 enzyme was structurally similar to known enzymes that can degrade even more hardy plastics such as PET bottles.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India Today
3 days ago
- India Today
At least 96 dead after receiving contaminated medical fentanyl in Argentina
Argentina is facing one of its most serious pharmaceutical scandals in decades, with up to 96 people reported dead after receiving hospital treatment with medical fentanyl contaminated by dangerous bacteria, according to The official death toll remains at 87. However, the Buenos Aires Herald reported that nine additional deaths are being examined to determine whether they are linked to the tainted TRACED TO MEDICAL FENTANYLThe crisis first came to light in May when dozens of patients in hospitals developed severe bacterial infections shortly after being administered fentanyl for pain relief or anaesthesia. Medical tests revealed the presence of Klebsiella pneumoniae and Ralstonia pickettii -- strains that, in several cases, were resistant to multiple traced the contamination to batches of fentanyl produced by pharmaceutical company HLB Pharma and its laboratory partner, Laboratorio Ramallo as reported by The drug regulator, Anmat, confirmed the presence of bacterial contamination both in samples taken from deceased patients and in ampoules from two specific fentanyl batches. One of these had been "widely circulated," federal judge Ernesto Kreplak, who is leading the investigation, told local DENIES DIRECT RESPONSIBILITYAriel Garca Furfaro, owner of HLB Pharma, rejected claims that the deaths could be directly linked to his company's product. In an interview with La Nación, he said the firm had voluntarily pulled the fentanyl from the market and suggested the contamination may have been deliberate contaminated medication was reportedly distributed to hospitals in Buenos Aires province, Santa Fe, Córdoba, Formosa and Buenos Aires city. Authorities believe more than 300,000 ampoules may have been affected, with approximately 45,000 administered before the rest were recalled and who received the contaminated fentanyl had been hospitalised for unrelated medical conditions but rapidly deteriorated after infection with the multidrug-resistant the contaminated batches have been recalled, new cases linked to the fentanyl continue to criminal charges have yet been filed, but 24 individuals connected to the manufacture and distribution of the fentanyl have been named as suspects. The court has imposed travel bans on them and frozen their IS THE MEDICAL USE OF FENTANYL?Fentanyl, a synthetic opioid approved for pain management and anaesthesia, is 50 to 100 times more potent than morphine. In this case, the contamination -- rather than the drug's chemical properties -- is blamed for the deaths, making it one of the most smost serious drug contamination incidents in Argentina's history.- Ends

The Hindu
4 days ago
- The Hindu
Guntur doctors cure drug-resistant bone infection with phage therapy
Doctors at SHRI Hospital, Guntur, have successfully treated a 72-year-old woman from Bapatla suffering from a chronic, multidrug-resistant bone and joint infection. The patient had battled Acinetobacter baumannii for six months — resistant to all available antibiotics — before being admitted in critical condition in January. Led by Dr K. Kalyan Chakravarthy, specialist in sepsis and infectious diseases, in collaboration with Prof. Gopal Nath of Banaras Hindu University, the team used bacteriophage therapy — viruses that target bacteria — assisted by orthopaedic surgeon Dr Raviteja Y. and anaesthetist Dr Ramakrishna K. The patient has had no recurrence in the past six months. Once common before antibiotics, phage therapy is regaining attention amid rising antimicrobial resistance. Properly purified, bacteriophages are considered safe and are being used worldwide under 'compassionate use' protocols for stubborn infections. Clinical trials are under way in the UK, U.S., and Europe.


Time of India
5 days ago
- Time of India
IIT Roorkee scientists reveal how this common herb could defeat world's most dangerous superbugs & enhance antibiotic power
A research team at IIT Roorkee has found that a natural compound called thymol may help weaken stubborn superbugs and improve the effectiveness of antibiotics. Thymol is a plant-based substance commonly found in thyme. The study suggests it can target persister cells , bacteria that survive treatment and cause long-lasting infections, especially in Acinetobacter baumannii . This bacterium is known for causing persistent and chronic infections in hospitals. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program The findings, published in the Antimicrobial Agents and Chemotherapy journal, also show that thymol may make powerful antibiotics like meropenem work better. Early results indicate that using thymol alongside meropenem increases the antibiotic's ability to fight infections. This could be a promising way to tackle persistent bacterial infections. Professor Ranjana Pathania, the lead researcher, said, 'Thymol's ability to break down bacterial persistence and boost existing antibiotics offers a hopeful path to address antimicrobial resistance .' Live Events She added, 'By focusing on persister cells, we may improve treatment for chronic and recurring infections.' The research team discovered that thymol attacks persister cells in several ways. It disrupts the bacteria's energy production, making survival harder. It also damages the bacteria's outer membrane, making them more vulnerable. Thymol produces reactive oxygen species (ROS) that stress and weaken bacteria. It also blocks bacterial efflux pumps, which can help antibiotics like meropenem work better. While these findings are encouraging, more research and clinical trials are needed to confirm thymol's use in real medical treatments. Professor K.K. Pant, Director of IIT Roorkee, said, 'Antimicrobial resistance is a major global problem. This study shows how natural compounds could help overcome persistent infections. It reflects our commitment to research that tackles important health challenges.' The next stage of research will focus on improving the thymol and meropenem combination and testing its potential through further studies. If successful in clinical trials, this approach could become a new weapon against antibiotic-resistant infections, the team said. Inputs from agencies